About Charles

Charles Gore was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 he set up The Hepatitis C Trust together with 3 friends who also had hepatitis C. In 2002 he did pegylated interferon and ribavirin treatment and successfully eradicated the virus.

He has continued to run the Trust, working extensively with Government Departments and the National Health Service (NHS) in the UK, championing the patient perspective. He was closely involved in the creation of the European Liver Patients Association and was elected its first President in 2004. In 2007 he organised a meeting of hepatitis patient organisations from around the world to agree on co-ordinated global action. From this emerged the decision to hold an annual World Hepatitis Day and to create a new NGO, the World Hepatitis Alliance, of which Charles is the President. As a result of advocacy by the Alliance and its members WHO adopted successive viral hepatitis resolutions in 2010 and 2014, making World Hepatitis Day an official day and mandating the creation of a global strategy to tackle viral hepatitis.

Charles sits on a number of national and international advisory bodies including various WHO hepatitis guidelines development groups and the WHO Director-General’s Strategic and Technical Advisory Committee for Viral Hepatitis.

This speaker will be presenting at the following session(s)

  • Strategic direction 2: interventions for impact and strategic direction 3: delivering for equity


    Day: 2 November

    Time: 09:30

    The second day of the Summit is dedicated to strategic directions 2 and 3, which cover the issues of "interventions for impact" and "delivering for equity".


    • Conclusions from the World Hepatitis Summit 2015 and progress made.
      Charles Gore, World Hepatitis Alliance
    • 5 core interventions to reach HBV and HCV elimination.
    • Dr. Yvan Hutin, World Health Organization
    • Access to treatment.
    • Shiba Phurailatpam, APN+
    • Diagnostics: present and future.
    • Dr. Saleem Kamili, US Centers for Disease Control and Prevention
    • Hepatitis C prevention and treatment for vulnerable (or marginalised) populations.
    • Professor Gregory Dore, Kirby Institute, UNSW Sydney and St Vincent’s Hospital, Sydney

    Session objectives:

    • Learn areas of innovation and neglected issues.
    • Hear about the core issues for elimination and equitable access.
    • Gain an overview of the main advocacy areas and gaps.
  • Access to treatment


    Day: 2 November

    Time: 15:30

    This closing panel session examines how to develop the uninterrupted supply of quality-assured vaccines, medicines, diagnostics and other commodities on which effective hepatitis programmes are dependent.

    Chair: Liudmyla Maistat, Medicines Patent Pool

    Chair: Charles Gore, World Hepatitis Alliance


    • Introduction to Intellectual Property.
    • Ellen ‘t Hoen, University Medical Centre Groningen
    • Patent opposition.
    • Direct price negotiations.
    • Compulsory licensing.
    • Voluntary licensing.
    • Greg Perry, Medicines Patent Pool
    • Open discussion with audience.


    • To provide an overview of key IP barriers to access hepatitis C treatment.
    • To review different approaches to overcoming price and IP barriers and the progress made.
    • To discuss the possibility for organisations and civil society groups applying different methods and approaches to scaling up access to hepatitis C treatment to be complementary in their strategies.